Iovance Biotherapeutics: Valuation Check Amid Reaffirmed Amtagvi Expectations and Governance Concerns

Iovance Biotherapeutics (IOVA) shares have declined 6.72% despite reaffirmed expectations for Amtagvi's commercial performance. The stock is trading at $2.22, a significant decline from its narrative fair value of $8.35. Analysts have a consensus price target of $9.1, with some predicting a price target of $20.0. However, there are concerns about execution and risk, and EMA approval and real-world demand for Amtagvi are key risks to the company's narrative.